Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective blood-brain barrier. The deal comes as Novartis weathers several pipeline setbacks, including trial failures for neuroscience drug candidates.
The post Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M appeared first on MedCity News.
